Total Payments
$45,702
2024 Payments
$3,480
Companies
50
Transactions
1,445
Medicare Patients
1,569
Medicare Billing
$196,663
Payment Breakdown by Category
Research$23,436 (51.3%)
Food & Beverage$20,739 (45.4%)
Consulting$1,295 (2.8%)
Education$232.15 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23,436 | 4 | 51.3% |
| Food and Beverage | $20,739 | 1,427 | 45.4% |
| Consulting Fee | $1,295 | 1 | 2.8% |
| Education | $232.15 | 13 | 0.5% |
Payments by Type
Research
$23,436
4 transactions
General
$22,266
1,441 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $23,436 | 4 | $0 (2022) |
| Amgen Inc. | $4,172 | 285 | $0 (2024) |
| UCB, Inc. | $2,955 | 122 | $0 (2024) |
| ABBVIE INC. | $2,210 | 142 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,587 | 142 | $0 (2024) |
| PFIZER INC. | $1,403 | 112 | $0 (2024) |
| Janssen Biotech, Inc. | $1,102 | 76 | $0 (2024) |
| GlaxoSmithKline, LLC. | $928.86 | 68 | $0 (2024) |
| Lilly USA, LLC | $908.08 | 57 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $894.35 | 53 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,480 | 241 | Amgen Inc. ($838.17) |
| 2023 | $3,663 | 235 | Amgen Inc. ($835.02) |
| 2022 | $3,610 | 236 | Amgen Inc. ($422.62) |
| 2021 | $2,594 | 167 | Amgen Inc. ($495.64) |
| 2020 | $4,774 | 158 | UCB, Inc. ($1,421) |
| 2019 | $24,134 | 142 | Eli Lilly and Company ($22,096) |
| 2018 | $1,471 | 109 | Amgen Inc. ($303.11) |
| 2017 | $1,976 | 157 | Amgen Inc. ($261.13) |
All Payment Transactions
1,445 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/19/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $8.38 | General |
| Category: Immunology | ||||||
| 12/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/18/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $9.62 | General |
| 12/16/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $9.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Dermatology | ||||||
| 12/09/2024 | Fresenius Kabi USA, LLC | Tyenne (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Biosimilars | ||||||
| 12/05/2024 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: IMMUNOLOGY | ||||||
| 12/04/2024 | GENZYME CORPORATION | KEVZARA (Biological) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Rheumatology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $9.13 | General |
| Category: Immunology | ||||||
| 12/04/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $2.97 | General |
| Category: Immunology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $15.31 | General |
| Category: IMMUNOLOGY | ||||||
| 11/27/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $14.11 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Lilly USA, LLC | TALTZ (Drug) | Food and Beverage | In-kind items and services | $19.41 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $8.94 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/14/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $12.18 | General |
| Category: Bone Health | ||||||
| 11/12/2024 | Organon Llc | RENFLEXIS (Drug), HADLIMA | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: INFLIXIMAB | ||||||
| 11/12/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/08/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | Eli Lilly and Company | $22,509 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | Eli Lilly and Company | $927.30 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 476 | 731 | $197,807 | $60,281 |
| 2022 | 8 | 393 | 633 | $186,671 | $60,369 |
| 2021 | 6 | 288 | 475 | $127,982 | $34,913 |
| 2020 | 8 | 412 | 728 | $117,523 | $41,101 |
Total Patients
1,569
Total Services
2,567
Medicare Billing
$196,663
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 133 | 236 | $92,276 | $28,097 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 119 | 182 | $50,778 | $17,437 | 34.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 63 | 63 | $30,303 | $9,282 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $5,460 | $1,770 | 32.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 21 | 27 | $3,807 | $1,223 | 32.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 37 | 42 | $3,066 | $1,009 | 32.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 36 | 74 | $9,223 | $773.90 | 8.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 28 | 54 | $1,944 | $507.88 | 26.1% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 24 | 38 | $950.00 | $180.24 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 135 | 293 | $114,563 | $39,155 | 34.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 78 | 78 | $37,518 | $12,546 | 33.4% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 75 | 125 | $9,125 | $3,158 | 34.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 45 | 52 | $14,508 | $3,083 | 21.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 13 | 15 | $4,200 | $1,170 | 27.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 11 | 13 | $1,833 | $674.05 | 36.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 21 | 34 | $4,096 | $379.48 | 9.3% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2022 | 15 | 23 | $828.00 | $204.41 | 24.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 134 | 281 | $92,658 | $25,982 | 28.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 29 | 29 | $11,626 | $3,523 | 30.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 45 | 53 | $13,623 | $3,121 | 22.9% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 17 | 23 | $5,862 | $1,449 | 24.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 38 | 48 | $2,850 | $503.55 | 17.7% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2021 | 25 | 41 | $1,363 | $333.94 | 24.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 166 | 343 | $71,825 | $24,980 | 34.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 75 | 123 | $17,815 | $6,641 | 37.3% |
About Dr. Priya Ramani, M.D
Dr. Priya Ramani, M.D is a Rheumatology healthcare provider based in Oldsmar, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093779712.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Priya Ramani, M.D has received a total of $45,702 in payments from pharmaceutical and medical device companies, with $3,480 received in 2024. These payments were reported across 1,445 transactions from 50 companies. The most common payment nature is "" ($23,436).
As a Medicare-enrolled provider, Ramani has provided services to 1,569 Medicare beneficiaries, totaling 2,567 services with total Medicare billing of $196,663. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Other Specialties Rheumatology
- Location Oldsmar, FL
- Active Since 04/12/2006
- Last Updated 02/10/2022
- Taxonomy Code 207RR0500X
- Entity Type Individual
- NPI Number 1093779712
Products in Payments
- Enbrel (Biological) $2,431
- Cimzia (Drug) $1,595
- XELJANZ (Drug) $1,304
- ACTHAR (Biological) $1,167
- COSENTYX (Biological) $1,051
- BENLYSTA (Biological) $918.47
- TALTZ (Drug) $833.88
- RINVOQ (Biological) $702.37
- KRYSTEXXA (Biological) $660.61
- LUPKYNIS (Drug) $619.49
- EVENITY (Biological) $609.98
- Humira (Biological) $567.58
- ORENCIA (Biological) $549.53
- COSENTYX (Drug) $476.45
- OFEV (Drug) $455.68
- TREMFYA (Drug) $451.91
- KEVZARA (Drug) $418.53
- REMICADE (Biological) $389.76
- SAPHNELO (Biological) $388.01
- RINVOQ (Drug) $324.42
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.